Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Improving Outcomes Assessment in Chronic GVHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00637689
Recruitment Status : Active, not recruiting
First Posted : March 18, 2008
Last Update Posted : March 30, 2023
University of Minnesota
Stanford University
Dana-Farber Cancer Institute
Vanderbilt University
Medical College of Wisconsin
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Center

Brief Summary:
The purpose of this study is to see if recent guidelines proposed by the National Institutes of Health for the diagnosis, staging, and response assessment of people with chronic GVHD can improve our understanding of this complication. We will accomplish our goals by studying a large number of people with chronic GVHD over several years using information collected from health care providers, patients, laboratory studies and diagnostic tests. Several transplant centers in the United States are collaborating on this project.

Condition or disease
Chronic Graft Versus Host Disease

Detailed Description:

Chronic graft-versus-host disease (GVHD) is one of the most devastating long-term complications after infusion of allogeneic hematopoietic stem cells, and it remains one of the major barriers to successful transplantation. Relatively little progress has been made in understanding and improving treatments for chronic GVHD over the last 20 years, and the survival rate after diagnosis of chronic GVHD has barely improved despite advances in supportive care. The National Institutes of Health convened a Consensus Conference on this topic in June 2004 and recently published its recommendations on improving research methods in a series of six papers.

In our study, we will establish a multi-center, observational, longitudinal cohort in order to improve outcomes assessment in chronic GVHD with the specific aims of (1) validating prognostic factors for risk stratification; and (2) defining significant variables for a chronic GVHD activity index that predicts short-term (provider perception of change, patient perception of change, and changes in immunosuppressive medications) and longer-term outcomes (overall survival, time to discontinuation of systemic immunosuppressive therapy, and functional impairments). This goal will be accomplished by assembling a large modern cohort of people with chronic GVHD at four large core transplant centers. Approximately 700 people (half prevalent cases, half incident cases) with chronic GVHD will be enrolled. Every 3-6 months we will collect both objective and subjective measures reflecting disease activity, response to therapy, detailed physician assessments about organ involvement, and patient self-assessments about symptoms, functional status, and quality of life. Data will be used to test published hypotheses and the new recommendations emanating from the NIH Consensus conference. We will also be able to provide the detailed data needed to understand modern trends in chronic GVHD incidence, manifestations, and response to treatment. These studies are needed to operationalize the recommendations of the NIH Consensus conference, advance our understanding of chronic GVHD, and enhance our ability to conduct clinical trials.

Layout table for study information
Study Type : Observational
Actual Enrollment : 601 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Improving Outcomes Assessment in Chronic GVHD
Actual Study Start Date : September 2007
Actual Primary Completion Date : May 2017
Estimated Study Completion Date : February 2025

Primary Outcome Measures :
  1. Overall survival [ Time Frame: 3 years ]
  2. Time to discontinuation of immunosuppression [ Time Frame: 3 years ]
  3. Functional impairments [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Provider perception of change [ Time Frame: 6 months ]
  2. Patient perception of change [ Time Frame: 6 months ]
  3. Changes in immunosuppressive medications [ Time Frame: 6 months ]

Biospecimen Retention:   Samples With DNA
Some centers are collecting serum, plasma, cells and urine.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
People with chronic GVHD

Inclusion Criteria:

  • Age greater than or equal to 2 years
  • Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis allowed
  • Clinical or histologic diagnosis of chronic GVHD (overlap syndrome with acute GVHD is allowed
  • Need for systemic treatment, defined as any medication or intervention delivered systemically, including extracorporeal photopheresis. If a patient only received topical or local therapy at diagnosis, but subsequently requires systemic treatment, they may be enrolled upon initiation of systemic therapy. (Note, these patients will be classified as incident or prevalent cases depending on time from chronic GVHD diagnosis, not start of systemic therapy)
  • If a prevalent case (defined as enrollment three or more months after chronic GVHD diagnosis), then subject must be within 2 years of stem cell infusion
  • If an incident case (enrollment less than 3 months after chronic GVHD diagnosis) then no limitation on time from transplantation
  • No evidence of primary disease relapseProgression-free for their malignancy at enrollment (no evidence of primary disease progression since transplant, although residual disease may still be present)
  • Evaluation at the transplant center at the time of study enrollment
  • Signed, informed consent and if applicable, child assent

Exclusion Criteria:

  • Inability to comply with study procedures
  • Anticipated survival less than 6 months due to co-morbid disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00637689

Layout table for location information
United States, California
Stanford University
Stanford, California, United States, 94305
United States, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering
New York, New York, United States, 10065
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Fred Hutchinson Cancer Center
University of Minnesota
Stanford University
Dana-Farber Cancer Institute
Vanderbilt University
Medical College of Wisconsin
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Stephanie J Lee, MD MPH Fred Hutchinson Cancer Center
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Fred Hutchinson Cancer Center Identifier: NCT00637689    
Other Study ID Numbers: FHCRC-2192.00
U01CA118953-01A1 ( U.S. NIH Grant/Contract )
IR-6531 ( Other Identifier: FHCRC )
RG1000709 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
First Posted: March 18, 2008    Key Record Dates
Last Update Posted: March 30, 2023
Last Verified: March 2023
Keywords provided by Fred Hutchinson Cancer Center:
Chronic graft versus host disease
Allogeneic hematopoietic cell transplantation
Response criteria
Surrogate endpoints
Natural history
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis Obliterans Syndrome
Graft vs Host Disease
Immune System Diseases
Organizing Pneumonia
Bronchiolitis Obliterans
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases